ALK and non-small cell lung carcinoma: We analyzed 108 patients with metastatic NSCLC who tested positive for ALK fusions by next-generation sequencing (NGS) and received ALK TKI treatment and divided them into two groups based on the ALK gene fusion breakpoints: typical (breakpoints in ALK intron 19) and atypical (breakpoints in other ALK introns/exons or atypical fusion partner).